Evidence map›Paper›PMID 28797108›Full record

ArticlePloS one2017

Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F.

S Pasteuning-Vuhman, K Putker, C L Tanganyika-de Winter, J W Boertje-van der Meulen, L van Vliet, M Overzier, J J Plomp, A Aartsma-Rus, M van Putten

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Genetic Deletion of the Purinergic ReceptorACS pharmacology & translational science · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Mouse models for muscular dystrophies: an overview.Disease models & mechanisms · 2020
    Review
  12. Article
  13. Article
  14. Natural disease history of the D2FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

S Pasteuning-VuhmanDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-5250-5620
K PutkerDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.
C L Tanganyika-de WinterDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.
J W Boertje-van der MeulenDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.
L van VlietDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.
M OverzierDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.
J J PlompDepartment of Neurology Leiden University Medical Centre, Leiden, The Netherlands.
A Aartsma-RusDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.
M van PuttenDepartment of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands.
Leiden University · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limb-girdle muscular dystrophy types 2D and 2F (LGMD 2D and 2F) are autosomal recessive disorders caused by mutations in the alpha- and delta sarcoglycan genes, respectively, leading to severe muscle weakness and degeneration. The cause of the disease has been well characterized and a number of animal models are available for pre-clinical studies to test potential therapeutic interventions. To facilitate transition from drug discovery to clinical trials, standardized procedures and natural disease history data were collected for these mouse models. Implementing the TREAD-NMD standardized operating procedures, we here subjected LGMD2D (SGCA-null), LGMD2F (SGCD-null) and wild type (C57BL/6J) mice to five functional tests from the age of 4 to 32 weeks. To assess whether the functional test regime interfered with disease pathology, sedentary groups were taken along. Muscle physiology testing of tibialis anterior muscle was performed at the age of 34 weeks. Muscle histopathology and gene expression was analysed in skeletal muscles and heart. Muscle histopathology and gene expression was analysed in skeletal muscles and heart. Mice successfully accomplished the functional tests, which did not interfere with disease pathology. Muscle function of SGCA- and SGCD-null mice was impaired and declined over time. Interestingly, female SGCD-null mice outperformed males in the two and four limb hanging tests, which proved the most suitable non-invasive tests to assess muscle function. Muscle physiology testing of tibialis anterior muscle revealed lower specific force and higher susceptibility to eccentric-induced damage in LGMD mice. Analyzing muscle histopathology and gene expression, we identified the diaphragm as the most affected muscle in LGMD strains. Cardiac fibrosis was found in SGCD-null mice, being more severe in males than in females. Our study offers a comprehensive natural history dataset which will be useful to design standardized tests and future pre-clinical studies in LGMD2D and 2F mice.

Indexed as

AnimalsCollagenFemaleLipid MetabolismMaleMice, 129 StrainMice, Inbred C57BLMuscle, SkeletalMuscular Dystrophies, Limb-GirdleMuscular Dystrophy, AnimalMyostatinSignal TransductionTranscriptomeTransforming Growth Factor betaCollagenMstn protein, mouseMyostatinTransforming Growth Factor beta

Identifiers

PMID28797108
PMCPMC5552258
OpenAlexW2742673766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.